Assessment of lipemia interference on phenobarbital quantification using particle-enhanced turbidimetric inhibition immunoassay with Dimension clinical chemistry system and comparison to high-performance liquid chromatography
- 1 June 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 38 (6) , 1140-1150
Abstract
Phenobarbital, an anti-seizure medication with a narrow therapeutic window, requires therapeutic drug monitoring (TDM) for safe and effective use. Lipemia is a well-known interferent in turbidimetric immunoassays, yet its impact on phenobarbital quantification compared with high-performance liquid chromatography (HPLC) has not been fully characterized. We evaluated the effect of lipemia on phenobarbital measurement using a particle-enhanced turbidimetric inhibition immunoassay (PETINIA; Dimension Xpand Plus clinical chemistry system, Siemens) versus HPLC. Simulated lipemic plasma was prepared by spiking normal canine plasma with lipid emulsion to achieve predefined lipemia indices. Naturally lipemic TDM samples (index ≥ 4; n = 40) and non-lipemic controls (index ≤ 3, n = 40) were also analyzed. Phenobarbital concentrations were compared before and after lipid reduction by double microcentrifugation using both methods. HPLC performance was stable across all lipemia indices, with consistent retention times (5.0 min), accuracy and precision within acceptance limits, and high linearity ( R ² > 0.999). In contrast, PETINIA had a significant positive bias in lipemic samples, with median bias increasing from 9.1% at index 1 to 100% at index 6. Bias was significantly higher in naturally lipemic samples (median: 74.5%) compared with non‑lipemic controls (1.2%; p < 0.001). PETINIA and HPLC had strong agreement in non-lipemic samples (Passing–Bablok regression, r = 0.99), but poor agreement and proportional positive bias in lipemic samples ( r = 0.16; slope CI [1.01, 1.89]). PETINIA overestimated phenobarbital concentrations in lipemic plasma. Microcentrifugation effectively mitigated lipemic interference and improved agreement with HPLC, supporting the use of microcentrifugation in clinical TDM workflows.Keywords
This publication has 31 references indexed in Scilit:
- The lipemia index: an efficient screening tool for identifying IgM paraprotein-mediated interference in the Beckman Coulter AU5800 uric acid assaysClinica Chimica Acta, 2025
- Narrow Therapeutic Index Drugs: FDA Experience, Views, and OperationsClinical Pharmacology & Therapeutics, 2024
- Evaluation of the Preanalytical Interference of Hemoglobin, Bilirubin, or Lipids in Therapeutic Drug Monitoring Assays on Beckman Coulter AU AnalyzersLaboratory Medicine, 2021
- High performance liquid chromatography: A versatile tool for assaying antiepileptic drugs in biological matricesJournal of Chromatography B, 2021
- Immunoassays and Issues With Interference in Therapeutic Drug Monitoring2016
- Effect of interference from hemolysis, icterus and lipemia on routine pediatric clinical chemistry assaysClinica Chimica Acta, 2015
- The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsyEpilepsy Research, 2000
- Evaluation of the Cloned Enzyme Donor Immunoassay for Measurement of Phenytoin and Phenobarbital in SerumTherapeutic Drug Monitoring, 1993
- Particle-enhanced turbidimetric inhibition immunoassay for theophylline evaluated with the Du Pont aca.Clinical Chemistry, 1984
- Simultaneous Quantitative Assay of Phenobarbital, Phenytoin, and p-Hydroxydiphenylhydantoin by HPLC and a Comparison with EMIT®Journal of Analytical Toxicology, 1980